Keep up to date on the latest medical news at MDLinx - FREE!


  • Stay current on the latest medical literature, research and clinical news
  • MD jobs and physician job search at our new medical job Career Center
  • Receive invitations to paid market research
  • Search Clinical Trials and Medical Conferences

register to view free medical at articles at MDLinx

Follow Us

Posts by category

MDLinx Blog - Medical News and more.

Current Articles | RSS Feed RSS Feed

FDA: Revised recommendations for cardiovascular monitoring and use of multiple sclerosis drug Gilenya (fingolimod)

  
  
  
  
  

FDA issues drug safety annoucement for multiple sclerosis drug Gilenya (fingolimod).

The U.S. Food and Drug Administration (FDA) has completed its evaluation of a report of a patient who died after the first dose of multiple sclerosis drug Gilenya (fingolimod). The agency also has evaluated additional clinical trial and postmarket data for Gilenya, including reports of patients who died of cardiovascular events or unknown causes. FDA could not definitively conclude that Gilenya was related to any of the deaths (see Data Summary, below). However, based on its reevaluation of the data, FDA remains concerned about the cardiovascular effects of Gilenya after the first dose. Data show that, although the maximum heart rate lowering effect of Gilenya usually occurs within 6 hours of the first dose, the maximum effect may occur as late as 20 hours after the first dose in some patients (See Data Summary).

For this reason, Gilenya is now contraindicated (FDA advises against its use) in patients with certain pre-existing or recent (within last 6 months) heart conditions or stroke, or who are taking certain antiarrhythmic medications. See CONTRAINDICATION section of the drug label2.

FDA continues to recommend that all patients starting Gilenya be monitored for signs of a slow heart rate (bradycardia) for at least 6 hours after the first dose. FDA is now recommending hourly pulse and blood pressure measurement for all patients starting Gilenya. Electrocardiogram (ECG or EKG) testing should be performed prior to dosing and at the end of the observation period. Cardiovascular monitoring should continue until any symptoms resolve.

Read full release here.

All Posts

Trending Medical Articles

Tuesday, Jul 15, 2014
Journal of Neurology, 07/15/2014 Martínez–Sánchez P, et al. – The goal was to analyze the impact of telestroke on the number of intravenous thrombolysis (IVT), door–to–needle times and stroke outcomes. The authors suggest that telestroke systems are effective, even between nearby hospitals, shortening door–to–needle time and improving stroke outcomes. ...Read More
Tuesday, Jul 15, 2014
Contemporary Clinical Trials , 07/15/2014 He P – et al. – The advancements in biotechnology and genetics lead to an increasing research interest in personalized medicine, where a patient's genetic profile or biological traits contribute to choosing the most effective treatment for the patient. Numerical results based on simulated survival data show that the proposed method could...Read More
Monday, Jul 7, 2014
Diabetologia - Clinical and Experimental Diabetes and Metabolism, 07/07/2014 Kahleova H, et al. – The aim of the study was to compare the effect of six (A6 regimen) vs two meals a day, breakfast and lunch (B2 regimen), on body weight, hepatic fat content (HFC), insulin resistance and beta cell function. Eating only breakfast and lunch reduced body weight, HFC, fasting plasma glucose,...Read More
Monday, Jul 7, 2014
Arthroscopy, 07/07/2014 Jung WH, et al. – The purpose of this study was to evaluate the efficacy of periarticular multimodal drug injection after medial opening–wedge high tibial osteotomy regarding the postoperative pain level. This prospective randomized study shows that intraoperative periarticular multimodal drug injections in patients undergoing medial opening–wedge high...Read More
Tuesday, Jul 15, 2014
BMC Musculoskeletal Disorders, 07/15/2014 Golovakha ML, et al. – Medial open wedge high tibial osteotomy is a well–established procedure for the treatment of unicompartmental osteoarthritis and symptomatic varus malalignment. Authors hypothesized that different fixation devices generate different fixation stability profiles for the various wedge sizes in a finite element (FE)...Read More